Analytical assay platforms for soluble target engagement biomarkers: old favorites and emerging technologies-Reference-Cited by-同舟云学术

Analytical assay platforms for soluble target engagement biomarkers: old favorites and emerging technologies

Published:2013-12 Issue:23 Volume:5 Page:2919-2931
ISSN:1757-6180
Container-title:Bioanalysis
language:en
Short-container-title:Bioanalysis

Author:

Goodman Joanne¹,Agoram Balaji²

Affiliation:

1. Medimmune, Cambridge, CB21 6GH, UK.

2. Medimmune, Cambridge, CB21 6GH, UK

Abstract

Quantification of soluble biomarkers is critical for assessing target engagement in both preclinical and clinical settings. Since the advent of the commonly used ELISA, there has been an array of immunoassay platforms to achieve this goal, and many researchers will have a favorite. This review will compare and contrast immunoassay technologies used by many pharmaceutical and CRO groups and highlight emerging assay platforms that may deliver more sensitive assays. Several case studies will be used throughout as the changing immunoassay landscape is discussed.

Publisher

Future Science Ltd

Subject

Medical Laboratory Technology,Clinical Biochemistry,General Pharmacology, Toxicology and Pharmaceutics,General Medicine,Analytical Chemistry

Link

http://www.future-science.com/doi/pdf/10.4155/bio.13.262

Reference27 articles.

1. PK–PD modeling of protein drugs: implications in assay development

2. Bioanalysis of target biomarker and PK/PD relevancy during the development of biotherapeutics

3. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data

4. Understanding and mitigating impact of immunogenicity on pharmacokinetic assays

5. Heterophilic antibodies: a problem for all immunoassays.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Screening Non-neutralizing Anti-idiotype Antibodies Against a Drug Candidate for Total Pharmacokinetic and Target Engagement Assay;The AAPS Journal;2024-01-24

2. Direct bioanalysis or indirect calculation of target engagement and free drug exposure: do we apply double standards?;Bioanalysis;2023-01

3. Development of novel ultra-sensitive IL-11 target engagement assays to support mechanistic PK/PD modeling for an anti-IL-11 antibody therapeutic;mAbs;2022-08-02

4. Nanobody-based microfluidic human Fc assay for preclinical plasma quantification of IgG1/1.1 and IgG1-Fc-conjugates;Journal of Immunological Methods;2022-03

5. Development of a Meso Scale Discovery ligand-binding assay for measurement of free (drug-unbound) target in nonhuman primate serum;Bioanalysis;2021-04